Probiotic Supplement BPOM Registration in Indonesia: Strain, CFU and Claim Requirements

A probiotic supplement is the one health supplement category where the active ingredient can die on the shelf. That single fact reshapes the entire registration file.

Because the active is a living organism rather than a fixed chemical dose, BPOM does not assess a probiotic the way it assesses a vitamin. It assesses the organism’s identity at strain level, the evidence attached to that specific strain, and proof that the declared count is still viable at the end of shelf life rather than only on the day of manufacture. A new or previously unassessed strain must clear its own evaluation before the finished product can even join the standard registration queue.

This guide is written for regulatory affairs teams, marketing authorisation holders and importers preparing a probiotic filing for Indonesia. It sets out how category and strain history determine the pathway, what the strain and CFU documentation actually has to prove, what changed between 2024 and 2026, and where these files break down. It reflects the position as of September 2026.

Why BPOM assesses probiotic supplements on a separate track

BPOM treats probiotics as a distinct risk category because live microorganisms carry characteristics that a vitamin or mineral does not: sensitivity to temperature and humidity, effects that are specific to each individual strain rather than shared across a species, potential biological risk, and a corresponding need for strong scientific evidence including clinical study data.

The delay this creates rarely comes from paperwork volume. It comes from sequencing. Brands routinely treat “probiotic” as a formulation detail slotted into an existing supplement dossier late in development, once everything else is locked. BPOM instead routes an unassessed strain through a dedicated strain assessment before the finished product can be queued at all, a step a vitamin-only supplement never encounters, and one that can add months to a timeline built on a conventional supplement schedule.

The practical consequence is that probiotic registration is a planning problem before it is a documentation problem. The two decisions that set your timeline, product category and strain status, are both made before a dossier exists.

Category first: health supplement, processed food, or quasi-medicine

A probiotic is not automatically a health supplement in Indonesia. Depending on its form, composition and positioning, the same organism can sit in a health supplement dossier, a processed food dossier, or in narrow cases a quasi-medicine one, and each category is governed by a different set of instruments, evaluated by a different directorate, and subject to different claim rules.

This matters more than it sounds. A fermented drink and a capsule containing the same strain are not the same regulatory object. Getting the category wrong is not a slow filing; it is a filing in the wrong queue, and the correction is a resubmission rather than an amendment.

For a borderline product, category determination is worth resolving before label copy, claim strategy or packaging artwork is commissioned, because all three depend on it. Our Food & Beverage Registration team can confirm whether a product is better classified as processed food. 

The regulatory framework governing probiotic supplements in Indonesia

Registration in this category draws on several instruments at once, and the most common surprise during evaluation comes from a brand that read the general registration rule and assumed it covered the rest.

We do not publish instrument numbers, promulgation dates or article-level cross-references here. That mapping is the working substance of a regulatory consultancy, and in this category the correct instrument is frequently not the obvious one, the shelf-life obligation most brands attribute to the labelling rule actually sits with two entirely different instruments.

What changed between 2024 and 2026, and what changes next

Four developments matter for anyone filing or maintaining a probiotic supplement in Indonesia right now.

• The labelling regulation for health supplements was promulgated in June 2024 with a 24-month window for products already holding a marketing authorisation to bring labelling into conformity. That window has now closed. Any legacy probiotic SKU still carrying pre-2024 label copy, including how the microorganism count, storage and serving conditions are presented, is exposed to administrative sanction rather than to a grace period. This is the single most overlooked live compliance item we see in this category.
• A dedicated stability testing guideline took effect in March 2025 and now governs how shelf life is established for health supplements. It aligns Indonesia to the ASEAN stability standard, fixes the country as tropical Climatic Zone IVB, and sets out laboratory eligibility. For a probiotic, this is the instrument that turns “CFU through shelf life” from a principle into a testable protocol.
• The probiotic assessment guideline was enacted in June 2025, socialised publicly from August 2025, and replaced the 2021 version. BPOM has framed it as a response to rising probiotic use, giving both applicants and evaluators a clearer technical path. It strengthens strain identification criteria, safety and benefit testing, the new-strain and new-combination evaluation procedure, and labelling detail.
• A revision of the general health supplement registration regulation entered public consultation in November 2025, alongside the parallel quasi-medicine regulation, to align both with Indonesia’s risk-based business licensing framework. A new government regulation on BPOM fees was issued in 2026. The substantive probiotic criteria are stable; the procedural surface around them is moving, so anything you read about fees or processing tiers predating these should be treated as stale.

Strain identity: what triggers a new-strain assessment

Strain level, not species level

Two products can list the same species and behave entirely differently once ingested, because a documented health benefit attaches to a specific strain rather than to the species as a whole. BPOM’s assessment reflects this. A probiotic supplement must identify its microorganism down to strain level, and the safety and benefit evidence on file has to belong to the strain actually used in the finished product, not to a related strain from the same species, however close the relationship looks on a taxonomy chart.

This is where recognised safety status in another market stops being useful. A strain designation recognised elsewhere does not carry into an Indonesian filing as a pre-clearance. It is evidence you can submit, not a step you can skip.

The self-assessment that comes first

Under the current probiotic guideline, an applicant must first determine whether the strain it intends to use already has a BPOM assessment on file. A previously assessed strain can move toward standard product registration. A new strain, or a combination of strains that has not been evaluated together before, requires a separate strain assessment application covering identification data, safety data and benefit evidence, before the finished product dossier can proceed.

Two consequences follow that catch brands out. First, a multi-strain blend is one product but several strain evaluations, and the least-documented strain becomes the pacing item for the whole file. Second, a combination is assessed as a combination: three strains each individually assessed do not automatically clear as a trio if that specific combination has not been evaluated.

Claims are the other trigger. The established approved claim in this category concerns support for digestive health. A claim reaching beyond that territory requires clinical evidence of its own, and clinical study design is not something to discover you need after the dossier is assembled.

CFU counts and the shelf-life problem

CFU stands for colony-forming units, the standard measure of live, viable microorganisms in a probiotic product. A declared count is only meaningful if it is still true when the product is consumed, not on the day it left the line.

BPOM requires evidence that the declared count remains viable to the end of shelf life. Since March 2025 the design of that evidence has been governed by a dedicated stability guideline, which sets out study design, how results are evaluated, and how the resulting shelf-life statement appears on the label. Indonesia is treated as tropical Climatic Zone IVB, and testing must be performed at a laboratory meeting the eligibility conditions in that guideline.

For imported probiotics this is the most common avoidable requery we see. Stability data generated for a temperate market does not answer a Zone IVB question, and a potency result taken at the point of manufacture does not answer a shelf-life question at all. Both gaps cost a full testing cycle to close, and neither is visible until BPOM asks.

On the count itself, BPOM has not published one universal minimum CFU figure applying to every strain and every claim. In our experience the required count is assessed case by case against the specific claim being made and the strain’s own benefit evidence, which means two products making similar-sounding digestive health claims can end up needing to demonstrate different counts depending on what their underlying data supports.

Indonesia’s own strain 

BPOM’s attention is not confined to imported strains. At an international probiotics seminar it hosted in August 2026, the agency pointed to Indonesia’s biodiversity, including microorganisms from traditional fermented foods and distinctive local ecosystems, as a strategic asset for future probiotic innovation, and encouraged researchers and industry to produce evidence across the full chain from organism identification through safety testing, clinical benefit and responsible claim construction.

Domestic food technology research has already characterised locally isolated strains along these lines. Work from Gadjah Mada University on organisms isolated from Indonesian traditional fermented foods, including strains designated Dad-13, FNCC-0250 and GMRMP-001, illustrates the depth of strain-level documentation, genome sequencing, safety assessment, compatibility testing, in vivo benefit work, that a strain assessment ultimately draws on. These are research strains, named here to show what the evidence package looks like, not to indicate registration status.

A note on the processed food species list

BPOM has established 16 microorganism types for use in processed food. That list belongs to the processed food regime and should not be read as an approved strain list for health supplements, a distinction worth holding firmly, because the two are frequently conflated. Even within processed food, every probiotic claim still requires scientific evaluation covering safety, strain identity and demonstrated health benefit.

On the claims side, a fermented milk product from PT Yakult Indonesia Persada containing Lacticaseibacillus paracasei strain Shirota is among those that have secured BPOM probiotic claim approval. It is a useful reference point precisely because the approval attaches to that specific strain, not to the product category, and not to the company’s portfolio generally.

How BPOM registration works for a probiotic supplement, step by step

The sequence below is an orientation map rather than a schedule. Because category and strain history determine the route, a correctly scoped file and a misscoped one do not belong on the same clock.

• Confirm the product category. Health supplement, processed food, or in narrow cases quasi-medicine. Each uses a different instrument set and a different evaluation route. Resolve this before label copy or claim strategy is commissioned.
• Check strain status. An already-assessed strain can move toward standard registration. A new strain, or a combination not previously evaluated together, needs its own assessment application first. For a blend, check every strain and the combination.
• Assemble the strain evidence. Strain identification data, safety data, benefit evidence, and clinical study documentation where the intended claim reaches beyond digestive health support.
• Build the product quality file. Formulation and manufacturing data, quality specifications, and stability data designed under the current guideline for tropical Zone IVB conditions, demonstrating the declared microorganism count through full shelf life.
• Draft labelling to the current rules. Claim wording, microorganism count disclosure, storage and serving instructions, all tested against the applicable claims and labelling instruments for your category before submission rather than after.
• File through the applicable BPOM registration channel. The applicable route depends on category. Pre-assessment checks completeness before technical evaluation begins.
• Plan for post-market obligations. BPOM retains authority to reassess an approved probiotic supplement where new safety or efficacy evidence emerges, so the evidence file is a live document rather than a closed one.

A short review before filing tends to catch these issues while they are still cheap. Our Health Supplements Registration team can review strain status and claim strategy against the current rules before you submit. 

Three scenarios from practice

The following are composites drawn from patterns that recur across probiotic filings. They do not describe an actual client, product or company.

The strain that was “already approved” somewhere else

A brand entering Indonesia assumed that because its probiotic strain carried recognised safety status in its home market, BPOM would treat it as effectively pre-cleared. The strain had never been assessed here. The finished-product filing was returned with a requirement to complete a strain assessment first, safety and benefit dossier included, before the product dossier could be queued at all. The timeline budgeted for a standard supplement registration roughly doubled.

One SKU, three strain reviews

A multi-strain digestive health formula combining three bacterial strains looked, to the brand’s marketing team, like a single product decision. To BPOM it was three strain evaluations feeding one registration, because each strain carries its own safety and benefit evidence requirement. Two of the three already had an assessment on file. The third did not, and became the pacing item for the entire filing.

CFU at manufacture is not CFU at shelf life

A manufacturer’s laboratory results confirmed the labelled colony-forming-unit count at the point of production. When BPOM asked for data showing the count held to the end of stated shelf life, the brand had none, because its stability programme had only ever measured potency at manufacture. Generating the missing data added a full testing cycle. Under the guideline in force since March 2025 this scenario is more avoidable than it used to be, because the design expectations are now set out explicitly rather than inferred.

Common mistakes we see in probiotic filings

• Assuming a strain’s approval status in another country transfers automatically into a BPOM filing.
• Treating a multi-strain blend as one review rather than one review per strain, plus the combination itself.
• Measuring CFU only at the point of manufacture, with no shelf-life stability data.
• Reusing stability data generated for a temperate market. Indonesia is assessed as tropical Zone IVB.
• Leaving legacy label copy unchanged after the labelling conformity window closed in mid-2026, on the assumption that an existing authorisation protects the label.
• Finalising label and marketing copy before product category and claim scope are confirmed.
• Writing a claim beyond digestive health support without the clinical evidence that claim tier requires.
• Treating “probiotic” as a formulation detail added late, rather than a distinct technical review track planned from the start.

None of these are fixed by a template. Category, strain history and claim wording interact differently for every formulation, which is why a category and strain review before a dossier is drafted saves time rather than just paperwork.

Get your probiotic supplement ready for BPOM review

Category and strain status set your timeline, and both are decided before a dossier exists. Sorting them out early is what keeps a probiotic filing on a predictable schedule instead of an open-ended one.

Book a Health Supplements Registration consultation with our regulatory team to map your strain evidence, CFU documentation and claim strategy before you file, so you know what BPOM will expect from your specific product rather than from the category in general.